PMID- 21995695
OWN - NLM
STAT- MEDLINE
DCOM- 20120131
LR  - 20181201
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 65
IP  - 11
DP  - 2011 Nov
TI  - Comparative rapid onset of efficacy between doxazosin gastrointestinal 
      therapeutic system and tamsulosin in patients with lower urinary tract symptoms 
      from benign prostatic hyperplasia: a multicentre, prospective, randomised study.
PG  - 1193-9
LID - 10.1111/j.1742-1241.2011.02759.x [doi]
AB  - AIMS: To compare the rapidity of improvement in lower urinary tract symptoms 
      (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and 
      tamsulosin in benign prostatic hyperplasia (BPH) patients. METHODS: A total of 
      207 patients were randomised to one of two groups for a 12-week daily treatment 
      with doxazosin-GITS 4 mg or tamsulosin 0.2 mg. The primary end-point was to 
      compare the early onsets of efficacy between the two drugs. This was assessed by 
      analysing the changes from baseline in the total International Prostate Symptom 
      Score (IPSS) in the early period of treatment. Secondary aims were to compare 
      improvements in obstructive/irritative subscore and quality of life (QoL) score 
      between the two groups, and to evaluate the adverse events (AEs) with the drugs. 
      RESULTS: After 12 weeks of treatment, both groups showed significant improvements 
      in IPSS scores (total, obstructive and irritative subscores, QoL score) from 
      baseline (p < 0.0001). However, the doxazosin-GITS group showed significantly 
      greater improvements in total IPSS and obstructive subscore than the tamsulosin 
      group in the early period (p < 0.05). Improvements in irritative subscore (within 
      4 weeks) and QoL score (during 12 weeks) were not significantly different between 
      the groups. The incidences of AEs were similar between the groups. CONCLUSION: In 
      this study, doxazosin-GITS showed significantly more rapid onset of efficacy and 
      similar AEs compared with tamsulosin in BPH patients with LUTS. We believe this 
      will probably improve patient compliance. Future studies with a larger number of 
      patients and a longer follow-up period will be required to confirm this.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Chung, M S
AU  - Chung MS
AD  - Yonsei University Health System, Gangnam Severance Hosipital, Seoul, Korea.
FAU - Lee, S H
AU  - Lee SH
FAU - Park, K K
AU  - Park KK
FAU - Yoo, S J
AU  - Yoo SJ
FAU - Chung, B H
AU  - Chung BH
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Adrenergic alpha-1 Receptor Antagonists)
RN  - 0 (Sulfonamides)
RN  - G3P28OML5I (Tamsulosin)
RN  - NW1291F1W8 (Doxazosin)
SB  - IM
MH  - Adrenergic alpha-1 Receptor Antagonists/*therapeutic use
MH  - Doxazosin/*therapeutic use
MH  - Humans
MH  - Lower Urinary Tract Symptoms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Sulfonamides/*therapeutic use
MH  - Tamsulosin
MH  - Treatment Outcome
EDAT- 2011/10/15 06:00
MHDA- 2012/02/01 06:00
CRDT- 2011/10/15 06:00
PHST- 2011/10/15 06:00 [entrez]
PHST- 2011/10/15 06:00 [pubmed]
PHST- 2012/02/01 06:00 [medline]
AID - 10.1111/j.1742-1241.2011.02759.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2011 Nov;65(11):1193-9. doi: 10.1111/j.1742-1241.2011.02759.x.